Sanofi

AlphaMedix (212Pb-DOTAMTATE) met all primary efficacy endpoints in the ALPHAMEDIX-02 phase 2 study, demonstrating clinically meaningful overall response rates in both treatment-naïve and previously treated patients with gastroenteropancreatic neuroendocrine tumors.

Bioxodes has appointed Philippe Monteyne, MD, PhD, a former GSK and Sanofi executive with extensive neurological expertise, as chairman of its Board of Directors to guide development of breakthrough stroke candidate BIOX-101.

Amgen's Phase III VESALIUS-CV trial met both primary endpoints, demonstrating that Repatha significantly reduces major adverse cardiovascular events in high-risk patients without prior heart attack or stroke.

Novavax and Sanofi have amended their collaboration agreement to expand Sanofi's license to include Matrix-M adjuvant in pandemic influenza vaccine candidate development through Phase 2.

Nigeria has signed a memorandum of understanding with China's Shanghai Haiqi Industrial Company Limited to establish what Chinese officials describe as Africa's first local insulin production facility.

Sanofi commits an additional $625 million to its corporate venture arm, bringing total assets under management to over $1.4 billion for strategic biotech investments.

A phase 2 trial demonstrated that 0.5 mg/kg antithymocyte globulin (ATG) preserves beta-cell function as effectively as the standard 2.5 mg/kg dose in newly diagnosed type 1 diabetes patients.

The global nanomedicine market is projected to grow from approximately $245 billion in 2023 to over $430 billion by 2028, driven by increasing adoption in oncology, neurology, and regenerative medicine.

Innate Pharma received FDA Breakthrough Therapy Designation for lacutamab in Sézary syndrome and is nearing completion of Phase 3 trial protocol preparation following regulatory discussions.

AllRock Bio raised $50 million in Series A funding co-led by Versant Ventures and Westlake BioPartners to advance ROC-101, a first-in-class oral pan-ROCK inhibitor exclusively licensed from Sanofi.